Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Long-Acting Injection”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT04907279
What this trial is testing

Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)

Who this might be right for
SchizophreniaSchizo Affective DisorderBipolar I Disorder
Otsuka Canada Pharmaceutical Inc. 200
Testing effectiveness (Phase 2)WithdrawnNCT06336434
What this trial is testing

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Who this might be right for
HIV-1-infectionPregnancyPostpartum
National Institute of Allergy and Infectious Diseases (NIAID)
Not applicableStudy completedNCT01698216
What this trial is testing

Switching From Consta® to Sustenna® in Patients With Schizophrenia

Who this might be right for
Schizophrenia
Seoul National University Hospital 50
Not applicableStudy completedNCT00458367
What this trial is testing

RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice

Who this might be right for
SchizophreniaPsychotic DisordersSchizoaffective Disorder
Janssen Pharmaceutica N.V., Belgium 5,296
Early research (Phase 1)Study completedNCT04484337
What this trial is testing

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

Who this might be right for
HIV Infections
ViiV Healthcare 138
Testing effectiveness (Phase 2)Looking for participantsNCT06505395
What this trial is testing

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Who this might be right for
Gastrointestinal Neuroendocrine Pancreatic Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 90
Large-scale testing (Phase 3)Looking for participantsNCT07057622
What this trial is testing

A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

Who this might be right for
NETS Ga68 Lu177
HTA Co., Ltd. 184
Testing effectiveness (Phase 2)Study completedNCT02710526
What this trial is testing

Phase II Pharmacokinetics Study of CAM2038

Who this might be right for
Opioid Use DisorderChronic Pain
Braeburn Pharmaceuticals 66
Early research (Phase 1)Study completedNCT04712734
What this trial is testing

Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

Who this might be right for
Schizophrenia
Vanda Pharmaceuticals 42
Early research (Phase 1)Study completedNCT03854409
What this trial is testing

A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder

Who this might be right for
SchizophreniaBipolar I Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. 72
Not applicableWithdrawnNCT00675532
What this trial is testing

Testing a Primary Care Model for the Treatment of Opioid Dependence Using Long-acting Injectable Naltrexone (Vivitrol).

Who this might be right for
Drug Dependence
Yale University
Early research (Phase 1)Ended earlyNCT02968121
What this trial is testing

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

Who this might be right for
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc. 22
Not applicableNot Yet RecruitingNCT07379658
What this trial is testing

Long-Acting Injectable HIV PrEP PROs

Who this might be right for
HIV Pre-exposure Prophylaxis
Anupama Raghuram MD 128
Post-approval studies (Phase 4)Study completedNCT00216671
What this trial is testing

Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

Who this might be right for
Schizophrenia
Janssen Pharmaceutica N.V., Belgium 220
Not applicableStudy completedNCT07268430
What this trial is testing

Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia

Who this might be right for
Schizophrenia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 256
Large-scale testing (Phase 3)Study completedNCT00216476
What this trial is testing

Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Who this might be right for
SchizophreniaPsychotic Disorders
Janssen-Cilag International NV 753
Not applicableEnded earlyNCT01334606
What this trial is testing

Evaluation of a 4mmx32G Pen Needle for Injection of Basal Insulin Doses Above 40 Units

Who this might be right for
Diabetes Mellitus, Type 2
Becton, Dickinson and Company 21
Large-scale testing (Phase 3)Study completedNCT00590577
What this trial is testing

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

Who this might be right for
Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 652
Post-approval studies (Phase 4)Study completedNCT00261430
What this trial is testing

A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.

Who this might be right for
Schizophrenia
Janssen, LP 650
Post-approval studies (Phase 4)Study completedNCT02697045
What this trial is testing

Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch

Who this might be right for
Schizophrenia
Abdi İbrahim Otsuka 23
Next Page